CTOP (TFA)

CTOP TFA is a potent and highly selective μ-opioid receptor antagonist. CTOP TFA antagonizes the acute analgesic effect and hypermotility. CTOP TFA enhances extracellular dopamine levels in the nucleus accumbens. CTOP TFA dose-dependently enhances locomotor activity[1][2].

Product Specifications

UNSPSC

12352209

Target

Opioid Receptor

Type

Peptides

Related Pathways

GPCR/G Protein; Neuronal Signaling

Applications

Neuroscience-Neuromodulation

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/ctop-tfa.html

Purity

99.84

Solubility

H2O : 50 mg/mL (ultrasonic)

Smiles

OC(C(F)(F)F)=O.O=C(N[C@@H]1CC2=CNC3=CC=CC=C23)[C@H](CC4=CC=C(O)C=C4)NC([C@@H](NC([C@@H](CC5=CC=CC=C5)N)=O)CSSC([C@@H](C(N[C@@H]([C@@H](C)O)C(N)=O)=O)NC([C@]([H])([C@@H](C)O)NC([C@H](CCCN)NC1=O)=O)=O)(C)C)=O.[x]

Molecular Formula

C50H67N11O11S2.xC2HF3O2

Molecular Weight

1062.27 (free base)

References & Citations

[1]Gulya K, et al. Central effects of the potent and highly selective μ opioid antagonist D-Phe-Cys-Tyr-D-Trp-Orn-Thr-Pen-Thr-NH2 (CTOP) in mice. Eur J Pharmacol. 1988 Jun 10;150 (3) :355-60.|[2]Badiani A, et al. Intra-VTA injections of the mu-opioid antagonist CTOP enhance locomotor activity. Brain Res. 1995 Aug 28;690 (1) :112-6.